Overview A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Status: Completed Trial end date: 2019-10-04 Target enrollment: Participant gender: Summary This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity. Phase: Phase 1 Details Lead Sponsor: Idera Pharmaceuticals, Inc.